- Home
- STTK vs LANV Comparison
STTK vs LANV Comparison
Compare STTK & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LANV
- Stock Information
- Founded
- STTK 2016
- LANV 2015
- Country
- STTK United States
- LANV China
- Employees
- STTK N/A
- LANV N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- STTK Health Care
- LANV Finance
- Exchange
- STTK Nasdaq
- LANV Nasdaq
- Market Cap
- STTK 173.6M
- LANV 196.8M
- IPO Year
- STTK 2020
- LANV N/A
- Fundamental
- Price
- STTK $3.75
- LANV $1.67
- Analyst Decision
- STTK Strong Buy
- LANV
- Analyst Count
- STTK 3
- LANV 0
- Target Price
- STTK $10.67
- LANV N/A
- AVG Volume (30 Days)
- STTK 126.1K
- LANV 91.1K
- Earning Date
- STTK 11-07-2024
- LANV 08-26-2024
- Dividend Yield
- STTK N/A
- LANV N/A
- EPS Growth
- STTK N/A
- LANV N/A
- EPS
- STTK N/A
- LANV N/A
- Revenue
- STTK $4,123,999.00
- LANV $409,961,427.00
- Revenue This Year
- STTK $164.45
- LANV N/A
- Revenue Next Year
- STTK N/A
- LANV $76.77
- P/E Ratio
- STTK N/A
- LANV N/A
- Revenue Growth
- STTK 380.09
- LANV N/A
- 52 Week Low
- STTK $1.33
- LANV $0.91
- 52 Week High
- STTK $11.76
- LANV $4.70
- Technical
- Relative Strength Index (RSI)
- STTK 53.46
- LANV 51.90
- Support Level
- STTK $3.60
- LANV $1.60
- Resistance Level
- STTK $3.82
- LANV $1.82
- Average True Range (ATR)
- STTK 0.22
- LANV 0.14
- MACD
- STTK 0.03
- LANV -0.01
- Stochastic Oscillator
- STTK 68.42
- LANV 40.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.